Medications are available to treat many mental disorders, but they’re only effective if patients adhere to the treatment. A distribution agreement between Beckman Coulter Inc. and Saladax Biomedical Inc. aims to improve patient outcomes by providing health care professionals with tests to assess treatment compliance and individual patient drug response.

At the AD/PD 2022 international conference on Alzheimer’s and Parkinson’s Diseases, AC Immune SA presented images showing its positron emission tomography (PET) tracer detecting pathological alpha-synuclein (a-syn) in human subjects’ brains. The abnormal accumulation of a-syn, a natively unfolded and soluble presynaptic protein, is a neuropathological feature of neurodegenerative disorders.

Oculogica Inc. has signed an agreement with Minnetronix Inc. to launch a diagnostic device that tracks eye movements to detect possible brain concussion, this after receiving FDA clearance in December for its fourth iteration of the artificial intelligence-driven, battery-operated Eyebox.